Organoids have extensive therapeutic potential and are increasingly opening up new avenues within regenerative medicine.

Source Nature Communications

Their clinical application is greatly limited by the lack of effective GMP-compliant systems for organoid expansion in culture.

Here, it’s envisaged that the use of extracellular matrix (ECM) hydrogels derived from decellularized tissues (DT) can provide an environment capable of directing cell growth.

These gels possess the biochemical signature of tissue-specific ECM and have the potential for clinical translation.

Gels from decellularized porcine small intestine (SI) mucosa/submucosa enable formation and growth of endoderm-derived human organoids, such as gastric, hepatic, pancreatic, and SI. ECM gels can be used as a tool for direct human organoid derivation, for cell growth with a stable transcriptomic signature, and for in vivo organoid delivery.

The development of these ECM-derived hydrogels opens up the potential for human organoids to be used clinically.